These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30092948)

  • 21. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
    Vinereanu D; Lopes RD; Mulder H; Gersh BJ; Hanna M; de Barros E Silva PGM; Atar D; Wallentin L; Granger CB; Alexander JH;
    Stroke; 2017 Dec; 48(12):3266-3273. PubMed ID: 29089455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADMA, subclinical changes and atrial fibrillation in the general population.
    Ramuschkat M; Appelbaum S; Atzler D; Zeller T; Bauer C; Ojeda FM; Sinning CR; Hoffmann B; Lackner KJ; Böger RH; Wild PS; Münzel T; Blankenberg S; Schwedhelm E; Schnabel RB;
    Int J Cardiol; 2016 Jan; 203():640-6. PubMed ID: 26580348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
    Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
    Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.
    Schnabel RB; Maas R; Wang N; Yin X; Larson MG; Levy D; Ellinor PT; Lubitz SA; McManus DD; Magnani JW; Atzler D; Böger RH; Schwedhelm E; Vasan RS; Benjamin EJ
    Am Heart J; 2016 Jun; 176():100-6. PubMed ID: 27264226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
    Vinereanu D; Wang A; Mulder H; Lopes RD; Jansky P; Lewis BS; Gersh BJ; Avezum A; Hanna M; Held C; Wallentin L; Granger CB; Alexander JH
    Heart; 2018 Aug; 104(15):1292-1299. PubMed ID: 29352007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
    Alexander KP; Brouwer MA; Mulder H; Vinereanu D; Lopes RD; Proietti M; Al-Khatib SM; Hijazi Z; Halvorsen S; Hylek EM; Verheugt FWA; Alexander JH; Wallentin L; Granger CB;
    Am Heart J; 2019 Feb; 208():123-131. PubMed ID: 30579505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
    Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
    BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
    Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
    Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
    J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial.
    Guimarães PO; Wojdyla DM; Alexander JH; Thomas L; Alings M; Flaker GC; Al-Khatib SM; Hanna M; Horowitz JD; Wallentin L; Granger CB; Lopes RD
    Int J Cardiol; 2017 Jan; 227():443-449. PubMed ID: 27852444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.
    Christersson C; Wallentin L; Andersson U; Alexander JH; Ansell J; De Caterina R; Gersh BJ; Granger CB; Hanna M; Horowitz JD; Huber K; Husted S; Hylek EM; Lopes RD; Siegbahn A
    J Thromb Haemost; 2014 Sep; 12(9):1401-12. PubMed ID: 24942912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
    Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
    Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
    Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
    Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.